Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Aklief
2. Cd5789
1. 895542-09-3
2. Cd5789
3. Cd-5789
4. 0j8rn2w0hk
5. 4-[3-(3-tert-butyl-4-pyrrolidin-1-ylphenyl)-4-(2-hydroxyethoxy)phenyl]benzoic Acid
6. 3''-(tert-butyl)-4'-(2-hydroxyethoxy)-4''-(pyrrolidin-1-yl)-[1,1':3',1''-terphenyl]-4-carboxylic Acid
7. 3''-tert-butyl-4'-(2-hydroxyethoxy)-4''-(pyrrolidin-1-yl)(1,1':3',1'')terphenyl-4-carboxylic Acid
8. Aklief
9. Trifarotene [inn]
10. Trifarotene [usan:inn]
11. Unii-0j8rn2w0hk
12. (1,1':3',1''-terphenyl)-4-carboxylic Acid, 3''-(1,1-dimethylethyl)-4'-(2-hydroxyethoxy)-4''-(1-pyrrolidinyl)-
13. [1,1':3',1''-terphenyl]-4-carboxylic Acid, 3''-(1,1-dimethylethyl)-4'-(2-hydroxyethoxy)-4''-(1-pyrrolidinyl)-
14. Aklief (tn)
15. Cd 5789
16. Trifarotene [mi]
17. Trifarotene (usan/inn)
18. Trifarotene [usan]
19. Trifarotene [who-dd]
20. Schembl381493
21. Gtpl9962
22. Chembl3707313
23. Dtxsid30237781
24. Trifarotene [orange Book]
25. Bcp31392
26. Ex-a2704
27. Bdbm50457548
28. Akos037649283
29. At10456
30. Db12808
31. Compound 15b [pmid: 29706423]
32. Bs-17812
33. Bt166038
34. Hy-100256
35. Cs-0018407
36. D11225
37. Cd5789; Cd-5789; Cd 5789
38. Q27236856
Molecular Weight | 459.6 g/mol |
---|---|
Molecular Formula | C29H33NO4 |
XLogP3 | 6.3 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 8 |
Exact Mass | 459.24095853 g/mol |
Monoisotopic Mass | 459.24095853 g/mol |
Topological Polar Surface Area | 70 Ų |
Heavy Atom Count | 34 |
Formal Charge | 0 |
Complexity | 647 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Trifarotene is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.
Treatment of ichthyoses
Treatment of acne
Trifarotene exerts its effects via agonism at retinoid receptors - these receptors function to alter DNA transcription, resulting in downstream modulation of the expression of various genes involved in acne pathogenesis. It may be associated with skin irritation and should not be applied to cuts, abrasions, or otherwise damaged skin. As trifarotene may result in photosensitivity, patients should be cautioned to avoid excess sun exposure and to use sunscreen and/or protective clothing if exposure is unavoidable.
Dermatologic Agents
Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)
D - Dermatologicals
D10 - Anti-acne preparations
D10A - Anti-acne preparations for topical use
D10AD - Retinoids for topical use in acne
D10AD06 - Trifarotene
Absorption
Systemic absorption of trifarotene is minimal. In a pharmacokinetic study involving 19 subjects, systemic concentrations were only quantifiable in 7 - steady state Cmax values ranged from undetectable (<5 pg/mL) to 10 pg/mL and AUC0-24h ranged from 75 to 104 pg.h/mL.
Route of Elimination
Trifarotene is eliminated primarily in the feces.
Trifarotene is rapidly metabolized in human hepatocytes - its observed half-life in human keratinocytes is >24 hours, whereas half-life in human liver microsomes is approximately 5 minutes. Metabolism of trifarotene is catalyzed primarily by CYP2C9, CYP3A4, CYP2C8, and, to a lesser extent, CYP2B6.
The terminal half-life of trifarotene is typically between 2 to 9 hours.
Trifarotene is a potent and selective agonist of retinoic acid receptor- (RAR-). It has significantly less activity at RAR- and RAR- (16- and 65-fold lower than activity at RAR-, respectively), and has no activity at retinoid X receptors (RXRs). Agonism at retinoic acid receptors results in dimerization, and the resulting receptor-ligand dimer binds to specific DNA regulatory sequences (retinoic acid response elements, or RAREs) in the promotor regions of retinoid-responsible genes. Downstream alterations to gene expression induced by binding to these regions is the principle mechanism through which trifarotene exerts its comedolytic, anti-inflammatory, and depigmenting effects. Like other retinoids, trifarotene influences the expression of a number of genes involved in retinoid metabolism, epidermal differentiation/proliferation, and epidermal response to stress. In addition, trifarotene appears to modulate retinoid-mediated pathways involved in proteolysis, skin hydration, and cell adhesion - modulation of these additional pathways has not been observed with other retinoids and may therefore be unique to trifarotene.
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Trifarotene manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Trifarotene, including repackagers and relabelers. The FDA regulates Trifarotene manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Trifarotene API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Trifarotene manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Trifarotene supplier is an individual or a company that provides Trifarotene active pharmaceutical ingredient (API) or Trifarotene finished formulations upon request. The Trifarotene suppliers may include Trifarotene API manufacturers, exporters, distributors and traders.
click here to find a list of Trifarotene suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Trifarotene DMF (Drug Master File) is a document detailing the whole manufacturing process of Trifarotene active pharmaceutical ingredient (API) in detail. Different forms of Trifarotene DMFs exist exist since differing nations have different regulations, such as Trifarotene USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Trifarotene DMF submitted to regulatory agencies in the US is known as a USDMF. Trifarotene USDMF includes data on Trifarotene's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Trifarotene USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Trifarotene suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Trifarotene as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Trifarotene API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Trifarotene as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Trifarotene and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Trifarotene NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Trifarotene suppliers with NDC on PharmaCompass.
Trifarotene Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Trifarotene GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Trifarotene GMP manufacturer or Trifarotene GMP API supplier for your needs.
A Trifarotene CoA (Certificate of Analysis) is a formal document that attests to Trifarotene's compliance with Trifarotene specifications and serves as a tool for batch-level quality control.
Trifarotene CoA mostly includes findings from lab analyses of a specific batch. For each Trifarotene CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Trifarotene may be tested according to a variety of international standards, such as European Pharmacopoeia (Trifarotene EP), Trifarotene JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Trifarotene USP).
LOOKING FOR A SUPPLIER?